Global factors are driving the growth of innovation in food production. Forecasters suggest that there will be a 70% increase in calorific demand by 2050 due to growth in world population2. At the same time, countries are committing to decreasing the output of greenhouse gases, more than 25% of which come from agriculture, forestry, and land-use change2. Additionally, in developed nations there is demand for alternative proteins led by a swing towards plant based vegetarian and vegan diets, with research showing that about 30% of UK adults plan to eat more meat-free products in 2021 than in 20203.

Whitetail Clean Energy is poised to be a 300MW NET Power station at Wilton International, Teesside, capturing and storing its carbon emissions offshore,creating a Net Zero emissions power plant. Major contribution to the ‘Levelling-up’ agenda with construction planned to commence following conclusion of engineering and the Governmental support process, potentially creating over 2,000 jobs during construction and 200 indirect and direct highly skilled jobs during operation. First backed by UK Government in 2012 for research and development, the project intends to scale up technology to full commercial deployment, supercharging UK progress towards becoming a Science and Technology powerhouse.

“This is a massive infrastructure project and Sembcorp are delighted that Wilton International has been chosen for part of this major investment,” Matthew said. “It’s one of the largest construction projects that Wilton International has seen in recent years and it’s very much in alignment with our commitment to decarbonise our industrial site. Two converter substations will be built on a 20-acre plot – the first for the Sofia Wind Farm, the second for the adjacent Dogger Bank C Offshore Wind Farm.

A challenging year for biotech and pharma companies Since early 2020, supply chains globally have been under great strain due to the effects of the pandemic on both trade and production. Biotech and pharma companies have faced the challenge of producing new vaccines, tests and treatments at a rate that would previously have been unthinkable, at a time when countries across the world have been under lockdown, with increasingly tight borders.